Med-Fine Capital focuses on investment in healthcare and life sciences. The team has a deep background in healthcare industry and rich experience in venture capital. Headquartered in Shanghai, with business all over China, adhering to the concept of "focusing on healthcare and life sciences, giving full play to capital value and returning trust", the company is committed to becoming the most competitive professional healthcare venture capital firm in the world. Since 2016, Med-Fine Capital has invested in more than 40 companies, including Mabworks Biotech, Hanyu Medical, Lynk Pharma, Immvira, Zion Pharma, Amcare Lab, Chosen Medtech, Genomeprecision, Surgnova Healthcare, Weimi Bio-tech, SAFE Pharma, PharmaLegacy, and BioNova Pharma.
